Spotlight Therapeutics Closes its Series A Financing Bringing the Total Raised to $30 Million

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors.

Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the human body. Spotlight's proprietary technology platform develops programmable CRISPR ribonucleoproteins (RNPs) optimized for in vivo cell-targeted delivery. The modular biologics approach is designed to avoid the complexity and toxicities associated with current cell, viral and nanoparticle delivery methods. Spotlight’s technology integrates the game-changing power of CRISPR with well-established biologics precepts. The company is advancing lead programs in hemoglobinopathies and immuno-oncology.